The development of neutralizing antibodies against SARS-CoV-2 and their common features

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liu Daisy, Lian, Chaoyang, Yeap, Leng-Siew, Meng, Fei-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799018/
https://www.ncbi.nlm.nih.gov/pubmed/33377928
http://dx.doi.org/10.1093/jmcb/mjaa070
_version_ 1783635092379271168
author Liu, Liu Daisy
Lian, Chaoyang
Yeap, Leng-Siew
Meng, Fei-Long
author_facet Liu, Liu Daisy
Lian, Chaoyang
Yeap, Leng-Siew
Meng, Fei-Long
author_sort Liu, Liu Daisy
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
format Online
Article
Text
id pubmed-7799018
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77990182021-01-25 The development of neutralizing antibodies against SARS-CoV-2 and their common features Liu, Liu Daisy Lian, Chaoyang Yeap, Leng-Siew Meng, Fei-Long J Mol Cell Biol Reviews Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features. Oxford University Press 2020-12-30 /pmc/articles/PMC7799018/ /pubmed/33377928 http://dx.doi.org/10.1093/jmcb/mjaa070 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reviews
Liu, Liu Daisy
Lian, Chaoyang
Yeap, Leng-Siew
Meng, Fei-Long
The development of neutralizing antibodies against SARS-CoV-2 and their common features
title The development of neutralizing antibodies against SARS-CoV-2 and their common features
title_full The development of neutralizing antibodies against SARS-CoV-2 and their common features
title_fullStr The development of neutralizing antibodies against SARS-CoV-2 and their common features
title_full_unstemmed The development of neutralizing antibodies against SARS-CoV-2 and their common features
title_short The development of neutralizing antibodies against SARS-CoV-2 and their common features
title_sort development of neutralizing antibodies against sars-cov-2 and their common features
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799018/
https://www.ncbi.nlm.nih.gov/pubmed/33377928
http://dx.doi.org/10.1093/jmcb/mjaa070
work_keys_str_mv AT liuliudaisy thedevelopmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT lianchaoyang thedevelopmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT yeaplengsiew thedevelopmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT mengfeilong thedevelopmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT liuliudaisy developmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT lianchaoyang developmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT yeaplengsiew developmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures
AT mengfeilong developmentofneutralizingantibodiesagainstsarscov2andtheircommonfeatures

Ejemplares similares